Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL28830303 | 1.00 | CPB1 (0.47) | CPB1ALDH1A1GAATACR1CTSL | |
| SCHEMBL7500672 | 0.93 | CPB1 (0.53) | CPB1ALDH1A1GAACTSLNAAA | |
| SCHEMBL19083298 | 0.93 | CPB1 (0.53) | CPB1ALDH1A1GAACTSLNAAA | |
| SCHEMBL12225513 | 0.93 | CPB1 (0.53) | CPB1ALDH1A1GAACTSLNAAA | |
| Hydrochloric Acid SCHEMBL31350678 | 0.91 | CPB1 (0.52) | CPB1ALDH1A1GAACTSLNAAA | |
| Trifluoroacetic Acid SCHEMBL3331266 | 0.85 | ALDH1A1 (0.56) | CPB1ALDH1A1GAACTSLNAAA | |
| SCHEMBL14809260 | 0.84 | CPB1 (0.50) | CPB1ALDH1A1GAATACR1NAAA | |
| SCHEMBL18969529 | 0.81 | ALDH1A1 (0.52) | CPB1ALDH1A1GAACTSLNAAA | |
| SCHEMBL5745326 | 0.81 | ALDH1A1 (0.52) | CPB1ALDH1A1GAACTSLNAAA | |
| SCHEMBL16683509 | 0.81 | ALDH1A1 (0.52) | CPB1ALDH1A1GAACTSLNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312336-B2 | Inhibitors of RAF kinases | Pierre Fabre Médicament (FR) | 2025-05-27 | — | — | US | disclosed |
| EP-4048259-A1 | INHIBITORS OF RAF KINASES | Kinnate Biopharma Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-114845711-A | Inhibitors of RAF kinase | 金耐特生物制药公司 | 2022-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312336-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | CPB1 4074/4885ALDH1A1 2750/4885GAA 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.